Amy W. Schulman, Director of Alnylam Pharmaceuticals ALNY, has filed 5 purchases and 5 sales on the open market. Over the past 12 months that comes to a net sale of $7,475. The latest trade was on 05/20.

AS

AS

Amy W. Schulman

Director

Company

Alnylam Pharmaceuticals ALNY

First filing

23/02/27

Trades

47 trades

Buys / sales

5 / 5

12-month net buying

−$7,475

Last trade

05/20

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Elevance HealthELV	Open-market sale	03/12	03/23	26 sh	$287.50	$7,475	−10.7%
Camp4 TherapeuticsCAMP	Open-market buy	25/09/11	25/09/11	1,307,189 sh2 trades	$1.53avg.	$1,999,999.17	No record
Fractyl HealthGUTS	Open-market buy	25/03/13	25/03/17	8,550 sh	$1.17	$10,003.5	No record
Camp4 TherapeuticsCAMP	Open-market buyAmendment	24/10/15	24/10/22	909,090 sh	$11.00	$9,999,990	No record
Camp4 TherapeuticsCAMP	Open-market buy	24/10/15	24/10/15	909,090 sh	$11.00	$9,999,990	No record
Alnylam PharmaceuticalsALNY	Open-market sale10b5-1 plan	24/06/25	24/06/27	8,500 sh	$240.00	$2,040,000	−50.2%
Alnylam PharmaceuticalsALNY	Open-market sale10b5-1 plan	24/05/29	24/05/31	21,700 sh3 trades	$148.60avg.	$3,224,546.17	−72.0%